FY2025 Earnings Forecast for WST Issued By Zacks Research

West Pharmaceutical Services, Inc. (NYSE:WST) – Investment analysts at Zacks Research lifted their FY2025 earnings per share estimates for shares of West Pharmaceutical Services in a report issued on Thursday, May 15th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will post earnings of $6.26 per share for the year, up from their prior estimate of $6.18. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q4 2025 earnings at $1.71 EPS, Q1 2026 earnings at $1.45 EPS, Q2 2026 earnings at $1.85 EPS, FY2026 earnings at $7.10 EPS and FY2027 earnings at $8.22 EPS.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, April 24th. The medical instruments supplier reported $1.45 EPS for the quarter, beating the consensus estimate of $1.22 by $0.23. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. The business had revenue of $698.00 million during the quarter, compared to analysts’ expectations of $685.24 million. During the same period last year, the firm earned $1.56 EPS. The company’s quarterly revenue was up .4% compared to the same quarter last year.

A number of other brokerages have also recently issued reports on WST. StockNews.com cut shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 price target on the stock in a report on Friday, February 14th. Stephens raised West Pharmaceutical Services to a “strong-buy” rating in a research note on Monday, April 21st. KeyCorp decreased their target price on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Finally, Evercore ISI initiated coverage on West Pharmaceutical Services in a report on Tuesday, March 18th. They issued an “outperform” rating and a $275.00 target price on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $332.50.

West Pharmaceutical Services Stock Performance

NYSE:WST opened at $215.51 on Monday. The firm’s fifty day simple moving average is $214.58 and its 200-day simple moving average is $273.47. The company has a quick ratio of 2.23, a current ratio of 2.79 and a debt-to-equity ratio of 0.08. The stock has a market cap of $15.48 billion, a PE ratio of 32.21, a price-to-earnings-growth ratio of 6.74 and a beta of 1.14. West Pharmaceutical Services has a fifty-two week low of $187.43 and a fifty-two week high of $352.33.

West Pharmaceutical Services Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 6th. Stockholders of record on Wednesday, July 30th will be issued a $0.21 dividend. The ex-dividend date of this dividend is Wednesday, July 30th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.39%. West Pharmaceutical Services’s dividend payout ratio (DPR) is 13.19%.

Institutional Trading of West Pharmaceutical Services

A number of large investors have recently made changes to their positions in WST. Fifth Third Wealth Advisors LLC purchased a new position in shares of West Pharmaceutical Services during the fourth quarter valued at approximately $207,000. Hennion & Walsh Asset Management Inc. raised its holdings in West Pharmaceutical Services by 17.4% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 3,909 shares of the medical instruments supplier’s stock valued at $1,280,000 after acquiring an additional 580 shares during the last quarter. Arkadios Wealth Advisors raised its holdings in West Pharmaceutical Services by 5.5% in the 4th quarter. Arkadios Wealth Advisors now owns 1,264 shares of the medical instruments supplier’s stock valued at $414,000 after acquiring an additional 66 shares during the last quarter. HB Wealth Management LLC lifted its stake in shares of West Pharmaceutical Services by 46.4% during the 4th quarter. HB Wealth Management LLC now owns 1,206 shares of the medical instruments supplier’s stock worth $395,000 after purchasing an additional 382 shares during the period. Finally, Artemis Investment Management LLP purchased a new stake in shares of West Pharmaceutical Services in the fourth quarter valued at $20,912,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.